|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases activity decreases expression |
ISO |
tetrandrine results in decreased activity of ABCB1A protein tetrandrine results in decreased expression of ABCB1 |
CTD |
PMID:17273824 PMID:19840446 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:17201889 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:26640276 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
tetrandrine results in increased expression of AIFM1 protein |
CTD |
PMID:26822499 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation decreases phosphorylation |
ISO |
tetrandrine results in increased phosphorylation of AKT1 protein tetrandrine results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:30549224 PMID:31255635 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atg12 |
autophagy related 12 |
increases expression |
ISO |
tetrandrine results in increased expression of ATG12 protein |
CTD |
PMID:26822499 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atg5 |
autophagy related 5 |
increases expression decreases expression |
ISO |
tetrandrine results in increased expression of ATG5 protein tetrandrine results in decreased expression of ATG5 protein |
CTD |
PMID:25266202 PMID:26822499 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
decreases expression |
ISO |
tetrandrine results in decreased expression of ATG7 protein |
CTD |
PMID:25266202 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
tetrandrine results in increased expression of BAK1 protein |
CTD |
PMID:26822499 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
tetrandrine results in increased expression of BAX protein |
CTD |
PMID:26822499 PMID:31255635 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects response to substance increases expression multiple interactions decreases expression |
ISO |
BCL2 protein affects the susceptibility to tetrandrine tetrandrine results in increased expression of BCL2 protein CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein] tetrandrine results in decreased expression of BCL2 mRNA; tetrandrine results in decreased expression of BCL2 protein |
CTD |
PMID:18495333 PMID:26302866 PMID:26822499 PMID:31255635 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
tetrandrine results in decreased expression of BCL2L1 protein |
CTD |
PMID:26822499 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions decreases expression |
ISO |
tetrandrine results in increased expression of BECN1 protein [sodium arsenite co-treated with tetrandrine] results in increased expression of BECN1 protein tetrandrine results in decreased expression of BECN1 protein |
CTD |
PMID:25266202 PMID:26822499 PMID:30123091 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
tetrandrine results in decreased expression of BID protein |
CTD |
PMID:26822499 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects binding decreases expression |
ISO |
tetrandrine binds to BIRC5 promoter tetrandrine results in decreased expression of BIRC5 mRNA |
CTD |
PMID:17968851 PMID:18495333 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp12 |
caspase 12 |
increases cleavage |
ISO |
tetrandrine results in increased cleavage of CASP12 protein |
CTD |
PMID:26822499 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
increases expression increases cleavage multiple interactions |
ISO |
tetrandrine results in increased expression of CASP3 protein tetrandrine results in increased cleavage of CASP3 protein 3-methyladenine inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]; tetrandrine results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:25266202 PMID:26302866 PMID:26822499 PMID:31255635 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases expression increases cleavage |
ISO |
tetrandrine results in increased cleavage of and results in increased activity of CASP8 protein tetrandrine results in increased expression of CASP8 protein tetrandrine results in increased cleavage of CASP8 protein |
CTD |
PMID:25266202 PMID:26822499 PMID:31255635 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
tetrandrine results in increased cleavage of and results in increased activity of CASP9 protein tetrandrine results in increased cleavage of CASP9 protein |
CTD |
PMID:25266202 PMID:26822499 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccna2 |
cyclin A2 |
increases expression |
ISO |
tetrandrine results in increased expression of CCNA2 protein |
CTD |
PMID:31255635 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
ISO |
tetrandrine results in increased expression of CCNB1 protein |
CTD |
PMID:31255635 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression affects expression |
ISO |
[sodium arsenite co-treated with tetrandrine] affects the expression of CCND1 protein; [sodium arsenite co-treated with tetrandrine] results in decreased expression of CCND1 protein tetrandrine results in decreased expression of CCND1 protein tetrandrine affects the expression of CCND1 protein |
CTD |
PMID:30123091 PMID:31255635 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
tetrandrine results in decreased expression of CDH1 protein |
CTD |
PMID:30549224 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
tetrandrine results in decreased expression of CDH2 protein |
CTD |
PMID:30549224 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression affects expression multiple interactions |
ISO |
tetrandrine results in increased expression of CDKN1A tetrandrine affects the expression of CDKN1A protein [sodium arsenite co-treated with tetrandrine] affects the expression of CDKN1A protein |
CTD |
PMID:19840446 PMID:30123091 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
[sodium arsenite co-treated with tetrandrine] results in increased expression of CDKN1B protein tetrandrine results in increased expression of CDKN1B protein |
CTD |
PMID:30123091 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
EXP |
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein] |
CTD |
PMID:17201889 PMID:22001142 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
tetrandrine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:27235791 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; [tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IFNG protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein] |
CTD |
PMID:26640276 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 protein]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein |
CTD |
PMID:26640276 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases glutathionylation |
ISO |
CYP3A4 protein results in increased glutathionylation of tetrandrine |
CTD |
PMID:21992520 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases glutathionylation increases response to substance multiple interactions |
ISO |
CYP3A5 protein results in increased glutathionylation of tetrandrine CYP3A5 protein results in increased susceptibility to tetrandrine CYP3A5 protein promotes the reaction [tetrandrine results in decreased abundance of Glutathione]; CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased abundance of Reactive Oxygen Species]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein] |
CTD |
PMID:21992520 PMID:26302866 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
tetrandrine results in increased expression of DDIT3 protein |
CTD |
PMID:26822499 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation |
ISO |
tetrandrine results in decreased phosphorylation of EGFR protein |
CTD |
PMID:30549224 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Endog |
endonuclease G |
decreases expression |
ISO |
tetrandrine results in decreased expression of ENDOG protein |
CTD |
PMID:26822499 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression |
ISO |
[arsenite co-treated with tetrandrine] results in decreased expression of ERBB2 protein tetrandrine results in decreased expression of ERBB2 protein |
CTD |
PMID:31934280 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
tetrandrine inhibits the reaction [Hexachlorocyclohexane results in increased expression of FOS mRNA] |
CTD |
PMID:10072926 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of FOXO3 protein; [sodium arsenite co-treated with tetrandrine] results in increased expression of FOXO3 protein; tetrandrine affects the expression of and affects the phosphorylation of FOXO3 protein |
CTD |
PMID:30123091 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions increases expression |
ISO |
[tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]; resveratrol inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA] |
CTD |
PMID:26640276 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
decreases expression |
ISO |
tetrandrine results in decreased expression of GRB2 protein |
CTD |
PMID:30549224 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression |
ISO |
tetrandrine results in decreased expression of GSK3B protein modified form |
CTD |
PMID:25266202 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
tetrandrine results in increased expression of HSPA5 protein |
CTD |
PMID:26822499 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
EXP ISO |
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] tetrandrine results in increased expression of ICAM1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [[arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tetrandrine results in increased expression of ICAM1 protein]; [arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein; [arsenite co-treated with tetrandrine] results in increased expression of ICAM1 protein |
CTD |
PMID:17201889 PMID:31934280 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IFNG protein] |
CTD |
PMID:26640276 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO |
[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA] |
CTD |
PMID:26640276 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions decreases expression |
ISO |
resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein] tetrandrine results in decreased expression of IL17A mRNA |
CTD |
PMID:26640276 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein] tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein] |
CTD |
PMID:22001142 PMID:26640276 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein] |
CTD |
PMID:26640276 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases phosphorylation |
ISO |
tetrandrine results in decreased phosphorylation of JUN protein |
CTD |
PMID:30549224 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lmna |
lamin A/C |
increases expression |
ISO |
tetrandrine results in increased expression of LMNA protein |
CTD |
PMID:31255635 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
tetrandrine results in increased expression of MAP1LC3B |
CTD |
PMID:26822499 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein] tetrandrine results in increased phosphorylation of MAPK1 protein [arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK1 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK1 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:22001142 PMID:31934280 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein] tetrandrine results in increased phosphorylation of MAPK3 protein [arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK3 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK3 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22001142 PMID:31934280 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
increases expression |
ISO |
tetrandrine results in increased expression of MCL1 protein |
CTD |
PMID:31255635 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
tetrandrine results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:30549224 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
EXP ISO |
tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein] tetrandrine results in decreased expression of MMP9 protein |
CTD |
PMID:22001142 PMID:30549224 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions decreases expression |
ISO |
[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine results in decreased expression of and results in decreased phosphorylation of MTOR protein tetrandrine results in decreased expression of MTOR protein; tetrandrine results in decreased expression of MTOR protein modified form |
CTD |
PMID:25266202 PMID:26822499 PMID:30123091 PMID:31255635 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:17201889 PMID:22001142 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
tetrandrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:22001142 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
tetrandrine results in increased cleavage of PARP1 protein |
CTD |
PMID:26822499 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
affects phosphorylation multiple interactions |
ISO |
tetrandrine affects the phosphorylation of PRKAA1 protein [sodium arsenite co-treated with tetrandrine] affects the phosphorylation of PRKAA1 protein |
CTD |
PMID:30123091 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases phosphorylation |
EXP ISO |
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein] tetrandrine results in decreased expression of and results in decreased activity of RELA protein tetrandrine results in increased phosphorylation of RELA protein |
CTD |
PMID:17201889 PMID:30549224 PMID:31255635 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rorc |
RAR-related orphan receptor C |
multiple interactions decreases expression |
ISO |
tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA] tetrandrine results in decreased expression of RORC mRNA |
CTD |
PMID:26640276 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases expression |
ISO |
tetrandrine results in decreased expression of RPS6 protein modified form |
CTD |
PMID:25266202 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
decreases expression |
ISO |
tetrandrine results in decreased expression of RAPTOR protein |
CTD |
PMID:25266202 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
tetrandrine results in increased expression of SFN protein |
CTD |
PMID:26822499 |
|
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
tetrandrine results in decreased expression of SNAI1 protein |
CTD |
PMID:30549224 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
decreases expression |
ISO |
tetrandrine results in decreased expression of SOS1 protein |
CTD |
PMID:30549224 |
|
NCBI chr 6:14,533,870...14,613,348
Ensembl chr 6:14,533,360...14,611,107
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
tetrandrine results in decreased expression of SQSTM1 protein |
CTD |
PMID:25266202 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:17201889 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein] |
CTD |
PMID:17201889 PMID:26640276 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
increases phosphorylation decreases expression |
ISO |
tetrandrine results in increased phosphorylation of ULK1 protein tetrandrine results in decreased expression of ULK1 protein |
CTD |
PMID:25266202 PMID:26822499 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
Noscapine promotes the reaction [Cisplatin results in increased expression of BAX protein] Noscapine results in increased expression of BAX protein |
CTD |
PMID:20674069 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Noscapine results in decreased expression of BCL2 protein Noscapine promotes the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:20674069 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases response to substance increases expression decreases expression multiple interactions |
ISO |
BIRC5 protein results in decreased susceptibility to Noscapine Noscapine results in increased expression of BIRC5 mRNA; Noscapine results in increased expression of BIRC5 protein Noscapine results in decreased expression of BIRC5 protein Noscapine promotes the reaction [Cisplatin results in decreased expression of BIRC5 protein] |
CTD |
PMID:20674069 PMID:22848370 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
[Noscapine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; Noscapine promotes the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP3 protein]; Noscapine results in increased expression of and results in increased cleavage of CASP3 protein Noscapine results in increased activity of CASP3 protein |
CTD |
PMID:20674069 PMID:22848370 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Noscapine promotes the reaction [Cisplatin results in increased expression of and results in increased cleavage of CASP9 protein]; Noscapine results in increased expression of and results in increased cleavage of CASP9 protein |
CTD |
PMID:20674069 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
Noscapine promotes the reaction [Cisplatin results in increased expression of CDKN1A protein] Noscapine results in increased expression of CDKN1A protein |
CTD |
PMID:20674069 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Noscapine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:18493746 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Noscapine results in increased degradation of and results in decreased expression of and results in decreased activity of HIF1A protein |
CTD |
PMID:16596621 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Noscapine results in increased cleavage of PARP1 protein |
CTD |
PMID:22848370 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Noscapine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Noscapine promotes the reaction [Cisplatin results in increased expression of TP53 protein]; Noscapine results in increased expression of and results in increased phosphorylation of TP53 protein Noscapine results in increased expression of TP53 protein |
CTD |
PMID:20674069 PMID:22848370 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases secretion |
ISO |
Noscapine results in decreased secretion of VEGFA protein |
CTD |
PMID:16596621 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdc14b |
cell division cycle 14B |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA |
CTD |
PMID:28843594 |
|
NCBI chr17:844,731...934,787
Ensembl chr17:844,685...933,235
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA |
CTD |
PMID:28843594 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Mir101a |
microRNA 101a |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 5:115,966,332...115,966,406
Ensembl chr 5:115,966,328...115,966,410
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mir192 |
microRNA 192 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr12:21,542,964...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pla2g12a |
phospholipase A2, group XIIA |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:218,436,450...218,452,760
Ensembl chr 2:218,436,513...218,452,740
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdc14b |
cell division cycle 14B |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA |
CTD |
PMID:28843594 |
|
NCBI chr17:844,731...934,787
Ensembl chr17:844,685...933,235
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA |
CTD |
PMID:28843594 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Mir101a |
microRNA 101a |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 5:115,966,332...115,966,406
Ensembl chr 5:115,966,328...115,966,410
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mir192 |
microRNA 192 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr12:21,542,964...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pla2g12a |
phospholipase A2, group XIIA |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:218,436,450...218,452,760
Ensembl chr 2:218,436,513...218,452,740
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdc14b |
cell division cycle 14B |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA |
CTD |
PMID:28843594 |
|
NCBI chr17:844,731...934,787
Ensembl chr17:844,685...933,235
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA |
CTD |
PMID:28843594 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Mir101a |
microRNA 101a |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 5:115,966,332...115,966,406
Ensembl chr 5:115,966,328...115,966,410
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mir192 |
microRNA 192 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr12:21,542,964...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pla2g12a |
phospholipase A2, group XIIA |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:218,436,450...218,452,760
Ensembl chr 2:218,436,513...218,452,740
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases activity |
ISO |
glaucine results in increased activity of ABCB1 protein |
CTD |
PMID:23273999 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein] |
CTD |
PMID:24709313 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
|
G |
Ache |
acetylcholinesterase |
increases chemical synthesis multiple interactions increases degradation |
ISO |
ACHE protein results in increased chemical synthesis of 6-O-monoacetylmorphine [ACHE protein results in increased degradation of 6-O-monoacetylmorphine] which results in increased chemical synthesis of Morphine; [ACHE protein results in increased metabolism of Heroin] which results in increased chemical synthesis of 6-O-monoacetylmorphine |
CTD |
PMID:30080993 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions increases chemical synthesis increases degradation |
ISO |
[BCHE protein results in increased degradation of 6-O-monoacetylmorphine] which results in increased chemical synthesis of Morphine; [BCHE protein results in increased metabolism of Heroin] which results in increased chemical synthesis of 6-O-monoacetylmorphine BCHE protein results in increased chemical synthesis of 6-O-monoacetylmorphine |
CTD |
PMID:30080993 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Ces1d |
carboxylesterase 1D |
affects binding multiple interactions increases chemical synthesis |
ISO |
6-O-monoacetylmorphine binds to CES1 protein Cocaine inhibits the reaction [CES1 protein results in increased chemical synthesis of 6-O-monoacetylmorphine] |
CTD |
PMID:8930175 PMID:9311626 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions increases chemical synthesis |
ISO |
CES2 protein results in increased hydrolysis of 6-O-monoacetylmorphine Cocaine inhibits the reaction [CES2 protein results in increased chemical synthesis of 6-O-monoacetylmorphine]; Cocaine inhibits the reaction [CES2 protein results in increased hydrolysis of 6-O-monoacetylmorphine] |
CTD |
PMID:8930175 PMID:9169443 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
allocryptopine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21419197 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
allocryptopine results in increased expression of CYP1A2 mRNA |
CTD |
PMID:21419197 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
|
G |
Amy1 |
amylase alpha 1 |
multiple interactions |
EXP |
Apomorphine results in increased secretion of and results in increased activity of AMY1A protein; Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Metoclopramide inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein] |
CTD |
PMID:21173550 |
|
NCBI chr 2:201,382,678...201,397,487
Ensembl chr 2:201,382,675...201,397,816
|
|
G |
Avp |
arginine vasopressin |
increases expression multiple interactions |
ISO |
Apomorphine results in increased expression of AVP protein Metoclopramide inhibits the reaction [Apomorphine results in increased expression of AVP protein] |
CTD |
PMID:16575035 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form] |
CTD |
PMID:25633564 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
decreases expression |
ISO |
Apomorphine results in decreased expression of BMPR1A mRNA |
CTD |
PMID:25633564 |
|
NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616
|
|
G |
Cck |
cholecystokinin |
multiple interactions decreases activity |
EXP |
Naloxone inhibits the reaction [CCK protein results in decreased activity of Apomorphine] |
CTD |
PMID:3561887 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Cckbr |
cholecystokinin B receptor |
affects response to substance |
ISO |
CCKBR protein affects the susceptibility to Apomorphine |
CTD |
PMID:11702094 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Apomorphine results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
Apomorphine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Apomorphine results in increased activity of DRD1 protein] [[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] |
CTD |
PMID:8103921 PMID:15985612 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects response to substance increases response to substance |
ISO EXP |
[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein] DRD2 protein affects the susceptibility to Apomorphine DRD2 protein results in increased susceptibility to Apomorphine |
CTD |
PMID:2571179 PMID:7520908 PMID:8103596 PMID:8103921 PMID:14639100 PMID:19497322 More...
|
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
increases response to substance |
ISO |
DRD3 protein results in increased susceptibility to Apomorphine |
CTD |
PMID:19497322 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Apomorphine results in increased expression of FOS protein |
CTD |
PMID:10904129 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases expression |
ISO |
Apomorphine results in decreased expression of FURIN mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
GDNF protein affects the susceptibility to [Apomorphine co-treated with Oxidopamine] |
CTD |
PMID:11771942 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gh1 |
growth hormone 1 |
increases secretion increases expression |
ISO |
Apomorphine results in increased secretion of GH1 protein Apomorphine results in increased expression of GH1 protein |
CTD |
PMID:993808 PMID:8889285 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions decreases secretion decreases expression |
ISO |
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] Apomorphine results in decreased secretion of HAMP protein modified form Apomorphine results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine] |
CTD |
PMID:8539317 |
|
NCBI chr 2:36,694,174...36,695,442
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
increases response to substance multiple interactions |
EXP |
HTR6 protein results in increased susceptibility to Apomorphine Ro4368554 inhibits the reaction [HTR6 protein results in increased susceptibility to Apomorphine] |
CTD |
PMID:17920665 |
|
NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein] |
CTD |
PMID:14599342 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases activity |
ISO |
Apomorphine results in increased activity of ODC1 protein |
CTD |
PMID:10354516 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Apomorphine inhibits the reaction [Reserpine results in increased expression of PENK mRNA] |
CTD |
PMID:17719177 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Prl |
prolactin |
decreases expression |
ISO |
Apomorphine results in decreased expression of PRL protein |
CTD |
PMID:8889285 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Pvalb |
parvalbumin |
affects expression |
EXP |
Apomorphine affects the expression of PVALB protein |
CTD |
PMID:15238432 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Rgs9 |
regulator of G-protein signaling 9 |
affects response to substance |
ISO |
RGS9 affects the susceptibility to Apomorphine |
CTD |
PMID:15728856 |
|
NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
EXP |
SHH protein modified form affects the susceptibility to [Apomorphine co-treated with Oxidopamine] |
CTD |
PMID:11771942 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Syt7 |
synaptotagmin 7 |
multiple interactions |
EXP |
[Reserpine co-treated with Apomorphine] results in increased expression of SYT7 mRNA |
CTD |
PMID:17719177 |
|
NCBI chr 1:207,031,369...207,093,787
Ensembl chr 1:207,031,592...207,089,026
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Apomorphine promotes the reaction [Reserpine results in increased expression of TAC1 mRNA] |
CTD |
PMID:17719177 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
berbamine results in decreased expression of BCL2L1 protein |
CTD |
PMID:19960011 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
berbamine results in decreased expression of BID protein |
CTD |
PMID:19960011 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression affects binding |
ISO |
berbamine results in decreased expression of BIRC5 mRNA; berbamine results in decreased expression of BIRC5 protein berbamine binds to BIRC5 promoter |
CTD |
PMID:17531122 PMID:17968851 PMID:19960011 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
berbamine results in increased activity of CASP3 protein |
CTD |
PMID:17531122 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
berbamine results in decreased expression of CCND1 protein |
CTD |
PMID:19960011 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases expression |
ISO |
berbamine results in decreased expression of CHUK protein |
CTD |
PMID:19960011 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases phosphorylation |
ISO |
berbamine results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:19960011 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
berbamine affects the localization of RELA protein |
CTD |
PMID:19960011 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases expression |
ISO |
berbamine results in increased expression of TNFAIP3 protein |
CTD |
PMID:19960011 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
berberine increases expression of abca1 protein in mouse liver and human hepatocytes |
RGD |
PMID:29505790 |
RGD:19165131 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Berberine results in increased expression of ABCB1A mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
Berberine results in increased expression of ABCB1B mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acan |
aggrecan |
decreases expression |
ISO |
Berberine results in decreased expression of ACAN mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:132,981,034...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA] Berberine results in decreased activity of ACHE protein |
CTD |
PMID:29170048 PMID:33844597 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
EXP |
Berberine results in decreased expression of ACTA2 protein |
CTD |
PMID:17973934 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity |
EXP ISO |
Berberine results in increased activity of AHR protein |
CTD |
PMID:16046213 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine results in decreased phosphorylation of AKT1 protein Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23954465 PMID:30138605 PMID:33325633 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein] |
CTD |
PMID:30138605 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Berberine results in decreased expression of AURKB mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Aurkc |
aurora kinase C |
increases expression |
ISO |
Berberine results in increased expression of AURKC mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:66,843,653...66,864,348
Ensembl chr 1:66,843,653...66,864,386
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BBC3 mRNA [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression increases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:23954465 PMID:24751971 PMID:25600690 PMID:26712469 PMID:30138605 More...
|
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
Berberine results in decreased expression of BCL2L1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA Berberine results in increased expression of BCL2L11 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein] |
CTD |
PMID:26478571 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects binding |
ISO |
Berberine binds to BIRC5 promoter |
CTD |
PMID:17968851 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity increases expression |
ISO EXP |
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Berberine results in increased activity of CASP8 protein |
CTD |
PMID:20656010 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO EXP |
Berberine results in increased cleavage of CASP9 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein |
CTD |
PMID:16505103 PMID:26712469 PMID:30138605 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] |
CTD |
PMID:20828602 PMID:24751971 PMID:25600690 PMID:30138605 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] |
CTD |
PMID:16391493 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND1 protein |
CTD |
PMID:16505103 PMID:33325633 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCNE1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccnt1 |
cyclin T1 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 7:129,687,146...129,718,082
Ensembl chr 7:129,691,209...129,717,871
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CD36 mRNA Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] |
CTD |
PMID:28038998 PMID:29408570 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDH2 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK4 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK6 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Berberine results in increased expression of CDKN1A protein |
CTD |
PMID:16505103 PMID:23747414 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Berberine results in increased expression of CDKN1B protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Berberine results in increased expression of CDKN1C mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
affects phosphorylation multiple interactions increases expression |
ISO |
Berberine affects the phosphorylation of CEBPB protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CEBPB mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
Berberine results in increased expression of CHEK1 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
ISO |
Berberine results in increased expression of CHEK2 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL10A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL1A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
decreases expression |
ISO |
Berberine results in decreased expression of COL2A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Berberine results in increased expression of CREBBP mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Berberine affects the localization of CYCS protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression multiple interactions |
ISO EXP |
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:16046213 PMID:22342832 PMID:24583342 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:22342832 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA] Berberine results in increased expression of CYP2B10 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B9 mRNA]; Berberine promotes the reaction [Streptozocin results in increased expression of CYP2B9 mRNA] Berberine results in increased expression of CYP2B9 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:22342832 PMID:25455889 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression multiple interactions decreases activity |
EXP ISO |
Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Berberine results in decreased activity of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] |
CTD |
PMID:21524698 PMID:30086269 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dzip3 |
DAZ interacting zinc finger protein 3 |
increases expression |
ISO |
Berberine results in increased expression of DZIP3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:51,823,235...51,893,353
Ensembl chr11:51,823,231...51,893,353
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Berberine results in decreased expression of EGFR protein |
CTD |
PMID:33325633 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Berberine results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Berberine results in increased expression of EP300 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein |
CTD |
PMID:33325633 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression multiple interactions increases expression |
ISO |
Berberine results in decreased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA] |
CTD |
PMID:26478571 PMID:29408570 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein |
CTD |
PMID:20564506 PMID:20656010 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Berberine results in increased expression of FASLG mRNA; Berberine results in increased expression of FASLG protein |
CTD |
PMID:20656010 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:26712469 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein |
CTD |
PMID:26712469 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gdf5 |
growth differentiation factor 5 |
decreases expression |
ISO |
Berberine results in decreased expression of GDF5 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 3:144,454,306...144,458,757
Ensembl chr 3:144,454,338...144,458,612
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein] |
CTD |
PMID:24751971 PMID:25455889 PMID:30138605 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of GPX1 mRNA] |
CTD |
PMID:24751971 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:20462044 PMID:23954465 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:24751971 PMID:25600690 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
H2ac12 |
H2A clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,486,315...42,486,880
Ensembl chr17:42,486,415...42,486,941
|
|
G |
H2ac4 |
H2A clustered histone 4 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,799,953...42,800,345
Ensembl chr17:42,799,652...42,800,381
|
|
G |
H2ax |
H2A.X variant histone |
increases expression decreases expression multiple interactions |
ISO |
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] |
CTD |
PMID:23363784 PMID:23747414 PMID:27311644 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,485,746...42,486,126
|
|
G |
H2bc9 |
H2B clustered histone 9 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,470,593...42,478,605
|
|
G |
H3c1 |
H3 clustered histone 1 |
decreases expression |
ISO |
Berberine results in decreased expression of H3C1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,367,824...41,368,902
Ensembl chr17:41,368,386...41,368,856
|
|
G |
H3f3a |
H3.3 histone A |
decreases expression |
ISO |
Berberine results in decreased expression of H3-3A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:92,533,294...92,544,903
Ensembl chr13:92,533,298...92,544,908
|
|
G |
H3f4 |
H3.4 histone |
decreases expression |
ISO |
Berberine results in decreased expression of H3-4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:43,740,797...43,741,207
|
|
G |
H4c3 |
H4 clustered histone 3 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C3 mRNA |
CTD |
PMID:27311644 |
|
|
|
G |
Hat1 |
histone acetyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of HAT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:40,548,250...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac5 |
histone deacetylase 5 |
increases expression |
ISO |
Berberine results in increased expression of HDAC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hdac8 |
histone deacetylase 8 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923
|
|
G |
Hdac9 |
histone deacetylase 9 |
decreases expression increases expression |
ISO |
Berberine results in decreased expression of HDAC9 mRNA Berberine results in increased expression of HDAC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] |
CTD |
PMID:29408570 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796
|
|
G |
Hist1h2ah |
histone cluster 1 H2A family member H |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,384,521...41,385,018
|
|
G |
Hist1h2bc |
histone cluster 1, H2bc |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,692,335...42,696,860
Ensembl chr17:42,694,723...42,696,642
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hist1h2bl |
histone cluster 1 H2B family member l |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,708,646...42,709,435
|
|
G |
Hist1h2bq |
histone cluster 1 H2B family member Q |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,432,100...41,441,487
Ensembl chr17:41,429,164...41,442,153
|
|
G |
Hist1h4b |
histone cluster 1 H4 family member B |
decreases expression |
ISO |
Berberine results in decreased expression of H4C9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370
|
|
G |
Hist2h2aa3 |
histone cluster 2 H2A family member A3 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC18 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,808,398...183,808,922
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,780,449...183,783,030
|
|
G |
Hist2h4 |
histone cluster 2, H4 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,831,601...183,831,996
Ensembl chr 2:183,825,994...183,832,048
|
|
G |
Hist3h2a |
histone cluster 3, H2a |
decreases expression |
ISO |
Berberine results in decreased expression of H2AW mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of HMOX1 protein Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein] |
CTD |
PMID:23954465 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein] |
CTD |
PMID:18563319 PMID:25455889 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
Berberine results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of IFNG mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein] Berberine results in increased expression of IGF1R protein |
CTD |
PMID:23954465 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA Berberine results in increased expression of IL10 mRNA |
CTD |
PMID:21867779 PMID:30138605 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA] |
CTD |
PMID:16391493 PMID:29170048 PMID:30138605 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
Berberine results in increased expression of IL2 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein] |
CTD |
PMID:30240693 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein] Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein] |
CTD |
PMID:28916288 PMID:29170048 PMID:30138605 PMID:30240693 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga1 |
integrin subunit alpha 1 |
increases expression |
ISO |
Berberine results in increased expression of ITGA1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects localization multiple interactions |
EXP |
Berberine affects the localization of JUN protein arsenic trioxide promotes the reaction [Berberine affects the localization of JUN protein] |
CTD |
PMID:18294404 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
EXP |
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdm1a |
lysine demethylase 1A |
increases expression |
ISO |
Berberine results in increased expression of KDM1A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdm4a |
lysine demethylase 4A |
increases expression |
ISO |
Berberine results in increased expression of KDM4A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501
|
|
G |
Kdm5b |
lysine demethylase 5B |
increases expression |
ISO |
Berberine results in increased expression of KDM5B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872
|
|
G |
Kdm6a |
lysine demethylase 6A |
increases expression |
ISO |
Berberine results in increased expression of KDM6A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062
|
|
G |
Kdm6b |
lysine demethylase 6B |
increases expression |
ISO |
Berberine results in increased expression of KDM6B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:54,120,716...54,142,212
Ensembl chr10:54,121,848...54,130,794
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
increases expression |
ISO |
Berberine results in increased expression of KMT5A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:32,139,353...32,167,777
Ensembl chr12:32,139,178...32,162,711
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] |
CTD |
PMID:18640378 PMID:20564506 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
LOC103690190 |
histone H2A type 1-E |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,707,863...42,708,420
|
|
G |
LOC684841 |
similar to CG31613-PA |
decreases expression |
ISO |
Berberine results in decreased expression of H3C10 mRNA |
CTD |
PMID:27311644 |
|
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
EXP |
Berberine results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:18294404 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA] |
CTD |
PMID:18294404 PMID:20462044 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of MCM2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mir19a |
microRNA 19a |
decreases expression |
ISO |
Berberine results in decreased expression of MIR19A mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993
|
|
G |
Mir92a1 |
microRNA 92a-1 |
decreases expression |
ISO |
Berberine results in decreased expression of MIR92A1 mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:92,181,336...92,181,413
Ensembl chr15:92,181,336...92,181,413
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Berberine results in increased expression of MMP13 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP14 protein] |
CTD |
PMID:18294404 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein] |
CTD |
PMID:18294404 PMID:33325633 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity multiple interactions |
ISO |
Berberine results in decreased activity of MMP9 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] |
CTD |
PMID:21963898 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of MTTP protein] |
CTD |
PMID:25455889 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions affects localization |
EXP |
arsenic trioxide promotes the reaction [Berberine affects the localization of MYC protein] |
CTD |
PMID:18294404 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein] |
CTD |
PMID:26712469 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression increases activity multiple interactions |
ISO EXP |
Berberine results in increased expression of NFE2L2 protein Berberine results in increased activity of NFE2L2 protein Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23523906 PMID:23954465 PMID:30818834 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:21963898 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23954465 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] |
CTD |
PMID:21095217 PMID:23523906 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
IEP |
Berberine reverses reaction [Carbon tetrachloride decreases Nqo1 mRNA in liver] |
RGD |
PMID:31432116 |
RGD:25823187 |
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21524698 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Berberine results in increased activity of NR1I3 protein |
CTD |
PMID:30818834 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nsd2 |
nuclear receptor binding SET domain protein 2 |
decreases expression |
ISO |
Berberine results in decreased expression of NSD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:76,833,194...76,911,304
Ensembl chr14:76,835,637...76,913,641
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of ODC1 protein] |
CTD |
PMID:18294404 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Omd |
osteomodulin |
increases expression |
ISO |
Berberine results in increased expression of OMD mRNA |
CTD |
PMID:26478571 |
|
NCBI chr17:15,060,217...15,068,441
Ensembl chr17:15,060,217...15,068,441
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:21320518 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein |
CTD |
PMID:16505103 PMID:26712469 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases response to substance increases expression decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] PPARG mRNA results in increased susceptibility to Berberine Berberine results in increased expression of PPARG mRNA Berberine results in decreased expression of PPARG mRNA |
CTD |
PMID:20564506 PMID:26478571 PMID:29408570 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prg4 |
proteoglycan 4 |
decreases expression |
ISO |
Berberine results in decreased expression of PRG4 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation |
ISO |
Berberine results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:28298333 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein |
CTD |
PMID:18294404 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions decreases activity |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein |
CTD |
PMID:18294404 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of PRMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345
|
|
G |
Prmt2 |
protein arginine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of PRMT2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:12,394,748...12,420,643
Ensembl chr20:12,394,798...12,420,643
|
|
G |
Prmt5 |
protein arginine methyltransferase 5 |
increases expression |
ISO |
Berberine results in increased expression of PRMT5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:27,968,893...27,978,291
Ensembl chr15:27,968,910...27,978,296
|
|
G |
Prmt6 |
protein arginine methyltransferase 6 |
increases expression |
ISO |
Berberine results in increased expression of PRMT6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:197,927,750...197,932,980
Ensembl chr 2:197,927,220...197,933,648
|
|
G |
Prmt7 |
protein arginine methyltransferase 7 |
increases expression |
ISO |
Berberine results in increased expression of PRMT7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:34,110,724...34,161,531
Ensembl chr19:34,110,747...34,162,577
|
|
G |
Prmt8 |
protein arginine methyltransferase 8 |
increases expression |
ISO |
Berberine results in increased expression of PRMT8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:160,535,813...160,618,193
Ensembl chr 4:160,535,813...160,617,930
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Berberine results in increased expression of PTEN protein |
CTD |
PMID:29408570 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] |
CTD |
PMID:21095217 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rbp4 |
retinol binding protein 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased secretion of RBP4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] |
CTD |
PMID:23523906 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
RGD1562378 |
histone H4 variant H4-v.1 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C14 mRNA |
CTD |
PMID:27311644 |
|
|
|
G |
Rln1 |
relaxin 1 |
affects binding increases expression multiple interactions |
EXP |
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA |
CTD |
PMID:22363579 |
|
NCBI chr 1:227,079,960...227,082,960
Ensembl chr 1:227,079,966...227,082,882
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Berberine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26478571 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Setd1b |
SET domain containing 1B, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD1B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934
|
|
G |
Setd2 |
SET domain containing 2, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:110,511,808...110,597,489
Ensembl chr 8:110,511,772...110,597,489
|
|
G |
Setd3 |
SET domain containing 3, actin histidine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:127,023,058...127,090,020
Ensembl chr 6:127,023,058...127,090,008
|
|
G |
Setd5 |
SET domain containing 5 |
increases expression |
ISO |
Berberine results in increased expression of SETD5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:146,217,172...146,294,896
Ensembl chr 4:146,217,180...146,294,894
|
|
G |
Setd6 |
SET domain containing 6, protein lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453
|
|
G |
Setd7 |
SET domain containing 7, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:135,562,683...135,605,468
Ensembl chr 2:135,562,683...135,605,468
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of SETDB1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506
|
|
G |
Setdb2 |
SET domain bifurcated histone lysine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of SETDB2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:33,553,657...33,606,586
Ensembl chr15:33,453,952...33,606,470
|
|
G |
Si |
sucrase-isomaltase |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA] |
CTD |
PMID:20229011 |
|
NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein] |
CTD |
PMID:26712469 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein |
CTD |
PMID:26712469 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions increases expression decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein |
CTD |
PMID:26712469 PMID:27311644 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
decreases expression |
ISO |
Berberine results in decreased expression of SLC27A5 mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc6a19 |
solute carrier family 6 member 19 |
multiple interactions |
EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein] |
CTD |
PMID:21073932 |
|
NCBI chr 1:29,586,205...29,604,960
Ensembl chr 1:29,586,195...29,604,962
|
|
G |
Smyd3 |
SET and MYND domain containing 3 |
affects expression |
ISO |
Berberine affects the expression of SMYD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:90,709,263...91,266,209
Ensembl chr13:90,709,270...91,266,253
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] |
CTD |
PMID:21095217 PMID:22775417 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:22775417 PMID:24751971 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
Berberine results in decreased expression of SOX9 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Berberine results in increased expression of SP7 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases expression |
ISO |
Berberine results in increased expression of SPARC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity |
ISO |
Berberine results in decreased activity of TERT protein |
CTD |
PMID:25265580 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression multiple interactions |
EXP |
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] |
CTD |
PMID:17973934 PMID:23523906 PMID:30138605 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] |
CTD |
PMID:21963898 PMID:30240693 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
ISO EXP |
Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:16391493 PMID:20656010 PMID:21095217 PMID:21867779 PMID:23523906 PMID:25600690 PMID:28533128 PMID:29170048 PMID:30240693 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
Berberine results in decreased activity of TOP1 protein |
CTD |
PMID:23747414 |
|
NCBI chr 3:149,293,658...149,375,405
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions affects response to substance |
ISO |
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine |
CTD |
PMID:23747414 |
|
NCBI chr10:83,946,186...83,975,694
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein |
CTD |
PMID:20656010 PMID:26712469 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
Berberine results in increased expression of TRAF1 protein |
CTD |
PMID:20656010 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Tstd1 |
thiosulfate sulfurtransferase like domain containing 1 |
increases expression |
ISO |
Berberine results in increased expression of TSTD1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:83,853,421...83,854,875
Ensembl chr13:83,822,035...83,854,885
|
|
G |
Ube2a |
ubiquitin-conjugating enzyme E2A |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:116,114,339...116,125,076
Ensembl chr X:116,113,875...116,125,070
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of UCP2 mRNA] |
CTD |
PMID:28533128 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Berberine results in decreased expression of VEGFA protein |
CTD |
PMID:33325633 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression |
ISO |
Berberine results in increased expression of VEGFC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr16:37,712,408...37,827,657
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
beta-funaltrexamine inhibits the reaction [Morphine results in decreased expression of CCL5 protein] |
CTD |
PMID:11106302 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
EXP ISO |
[beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] inhibits the reaction [Morphine results in increased abundance of 3,4-Dihydroxyphenylacetic Acid]; [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] inhibits the reaction [Morphine results in increased abundance of Homovanillic Acid]; [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Morphine [beta-funaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Nicotine |
CTD |
PMID:8884884 PMID:15778877 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
multiple interactions |
EXP |
Bicuculline inhibits the reaction [Propofol results in decreased expression of ARC protein] |
CTD |
PMID:18946287 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Bicuculline co-treated with Ethanol] results in increased cleavage of CASP3 protein |
CTD |
PMID:29044621 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation |
EXP |
Bicuculline results in increased phosphorylation of CREB1 protein |
CTD |
PMID:22534176 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
[Bicuculline co-treated with Ethanol] results in increased phosphorylation of ERN1 protein |
CTD |
PMID:29044621 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions decreases expression |
EXP ISO |
Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form] Bicuculline results in decreased expression of GABRA1 mRNA |
CTD |
PMID:1977069 PMID:9600394 PMID:27720918 PMID:29038840 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
multiple interactions |
ISO |
Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form] |
CTD |
PMID:29038840 |
|
NCBI chr14:37,096,995...37,230,030
Ensembl chr14:37,097,279...37,228,944
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
multiple interactions |
EXP ISO |
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form] |
CTD |
PMID:27720918 PMID:29038840 |
|
NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
multiple interactions |
EXP ISO |
Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]] Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form] |
CTD |
PMID:1977069 PMID:29038840 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
EXP ISO |
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]] |
CTD |
PMID:27720918 PMID:29038840 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
decreases expression multiple interactions |
EXP ISO |
Bicuculline results in decreased expression of GABRB3 mRNA Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form] |
CTD |
PMID:9600394 PMID:29038840 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gabrg1 |
gamma-aminobutyric acid type A receptor subunit gamma 1 |
decreases expression |
EXP |
Bicuculline results in decreased expression of GABRG1 mRNA |
CTD |
PMID:9600394 |
|
NCBI chr14:37,396,217...37,469,606
Ensembl chr14:37,396,294...37,635,956
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
EXP ISO |
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form] |
CTD |
PMID:27720918 PMID:29038840 |
|
NCBI chr10:26,376,805...26,463,680
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
Bicuculline affects the reaction [bisphenol A affects the secretion of GNRH1 protein]; Bicuculline promotes the reaction [manganese chloride results in increased secretion of GNRH1 protein] |
CTD |
PMID:18603625 PMID:26950200 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Bicuculline promotes the reaction [Ethanol results in increased activity of GPT protein] |
CTD |
PMID:29044621 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions |
EXP |
Bicuculline results in decreased expression of and results in decreased localization of GRIA1 protein |
CTD |
PMID:19674091 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions decreases expression |
EXP ISO |
Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; Bicuculline results in decreased expression of and results in decreased localization of GRIA2 protein; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline results in decreased expression of GRIA2 mRNA; Bicuculline results in decreased expression of GRIA2 protein |
CTD |
PMID:19674091 PMID:22262897 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
multiple interactions |
ISO |
[Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein |
CTD |
PMID:19911010 |
|
NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
|
|
G |
Hdac5 |
histone deacetylase 5 |
multiple interactions |
EXP |
[Bicuculline co-treated with 4-Aminopyridine] affects the localization of HDAC5 protein |
CTD |
PMID:15773917 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
[Bicuculline co-treated with Ethanol] results in increased expression of MAP3K5 protein |
CTD |
PMID:29044621 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP ISO |
Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK1 protein] [Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19344668 PMID:19911010 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP ISO |
Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK3 protein] [Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19344668 PMID:19911010 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Bicuculline co-treated with Ethanol] results in increased expression of MAPK8 protein |
CTD |
PMID:29044621 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
multiple interactions increases phosphorylation increases expression |
ISO EXP |
MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline results in increased phosphorylation of MECP2 protein Bicuculline results in increased expression of MECP2 mRNA |
CTD |
PMID:22262897 |
|
NCBI chr X:151,781,177...151,844,687
Ensembl chr X:151,789,930...151,844,689
|
|
G |
Mpdz |
multiple PDZ domain crumbs cell polarity complex component |
affects response to substance |
ISO |
MPDZ protein affects the susceptibility to Bicuculline |
CTD |
PMID:14960011 |
|
NCBI chr 5:95,766,112...95,920,531
Ensembl chr 5:95,766,118...95,920,499
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein] |
CTD |
PMID:15773917 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Bicuculline inhibits the reaction [Propofol inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]; Bicuculline inhibits the reaction [Thiopental inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]] |
CTD |
PMID:11991087 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Oxtr |
oxytocin receptor |
multiple interactions |
EXP |
Bicuculline inhibits the reaction [oxytocin, Thr(4)-Gly(7)- results in increased activity of OXTR protein] |
CTD |
PMID:11069593 |
|
NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
EXP |
[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]] |
CTD |
PMID:15773917 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Ryr1 |
ryanodine receptor 1 |
increases response to substance |
EXP |
RYR1 results in increased susceptibility to Bicuculline |
CTD |
PMID:22534176 |
|
NCBI chr 1:84,292,578...84,423,799
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
Ryr2 |
ryanodine receptor 2 |
increases response to substance |
EXP |
RYR2 results in increased susceptibility to Bicuculline |
CTD |
PMID:22534176 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
Bicuculline promotes the reaction [Reserpine affects the activity of TH protein]; Bicuculline promotes the reaction [Reserpine results in increased expression of TH mRNA] |
CTD |
PMID:1981253 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases expression |
EXP |
boldine results in increased expression of ABCB11 mRNA; boldine results in increased expression of ABCB11 protein |
CTD |
PMID:25771127 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
boldine results in increased expression of ABCC2 mRNA |
CTD |
PMID:25771127 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Aqp8 |
aquaporin 8 |
increases expression |
EXP |
boldine results in increased expression of AQP8 mRNA |
CTD |
PMID:25771127 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
boldine inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of CAT protein] |
CTD |
PMID:32531310 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding multiple interactions |
EXP |
boldine analog binds to DRD1 protein boldine analog inhibits the reaction [SCH 23390 binds to DRD1 protein] |
CTD |
PMID:10785418 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
boldine inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein] |
CTD |
PMID:32531310 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
EXP |
boldine results in increased expression of NR0B2 mRNA |
CTD |
PMID:25771127 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases expression |
EXP |
boldine results in increased expression of NR1H4 mRNA |
CTD |
PMID:25771127 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
increases expression |
EXP |
boldine results in increased expression of SLC4A2 mRNA |
CTD |
PMID:25771127 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Tert |
telomerase reverse transcriptase |
affects splicing decreases activity |
ISO |
boldine affects the splicing of TERT mRNA boldine results in decreased activity of TERT protein |
CTD |
PMID:25746354 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
boldine inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of TNF protein] |
CTD |
PMID:32531310 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
EXP |
boldine results in increased expression of UGT1A1 mRNA |
CTD |
PMID:25771127 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
EXP |
Buprenorphine results in decreased expression of BDNF protein |
CTD |
PMID:24321744 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
EXP ISO |
Buprenorphine results in decreased activity of CAT protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Buprenorphine] results in increased activity of CAT protein |
CTD |
PMID:25683329 PMID:32113805 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases phosphorylation |
EXP |
Buprenorphine results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:24321744 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects metabolic processing |
ISO |
CYP2C8 protein affects the metabolism of Buprenorphine |
CTD |
PMID:16010532 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing decreases activity |
ISO |
CYP2D6 protein results in increased metabolism of Buprenorphine Buprenorphine results in decreased activity of CYP2D6 protein |
CTD |
PMID:12756210 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing decreases alkylation increases metabolic processing decreases activity |
ISO |
CYP3A4 protein affects the metabolism of Buprenorphine CYP3A4 protein results in decreased alkylation of Buprenorphine CYP3A4 protein results in increased metabolism of Buprenorphine Buprenorphine results in decreased activity of CYP3A4 protein |
CTD |
PMID:12756210 PMID:15966752 PMID:16010532 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases activity |
EXP |
Buprenorphine results in increased activity of GPT protein |
CTD |
PMID:25683329 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Il2 |
interleukin 2 |
decreases expression |
ISO |
Buprenorphine results in decreased expression of IL2 mRNA |
CTD |
PMID:23965172 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
Buprenorphine results in increased expression of IL4 mRNA |
CTD |
PMID:23965172 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Buprenorphine results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:23965172 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Buprenorphine results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:23965172 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
decreases phosphorylation |
EXP |
Buprenorphine results in decreased phosphorylation of NTRK2 protein |
CTD |
PMID:24321744 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
affects binding multiple interactions |
EXP ISO |
Buprenorphine binds to OPRD1 protein Buprenorphine inhibits the reaction [Enkephalin, D-Penicillamine (2,5)- analog binds to OPRD1 protein] |
CTD |
PMID:7562497 PMID:21866885 |
|
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
affects binding multiple interactions |
EXP ISO |
Buprenorphine binds to OPRK1 protein Buprenorphine inhibits the reaction [U 69593 binds to OPRK1 protein] |
CTD |
PMID:7562497 PMID:21866885 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
multiple interactions |
ISO |
Buprenorphine binds to and results in increased activity of OPRL1 protein |
CTD |
PMID:10998549 |
|
NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions affects binding |
ISO EXP |
Buprenorphine binds to and affects the activity of OPRM1 protein; Buprenorphine binds to and results in increased activity of OPRM1 protein; Buprenorphine inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] Buprenorphine binds to OPRM1 protein |
CTD |
PMID:7562497 PMID:16010532 PMID:21866885 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
decreases activity |
EXP |
Buprenorphine results in decreased activity of PRKACA protein |
CTD |
PMID:24321744 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of Buprenorphine |
CTD |
PMID:12756209 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
affects activity |
EXP |
Butorphanol affects the activity of OPRD1 protein |
CTD |
PMID:17909753 |
|
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
affects activity |
EXP |
Butorphanol affects the activity of OPRK1 protein |
CTD |
PMID:17909753 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
affects activity increases activity |
ISO EXP |
Butorphanol affects the activity of OPRM1 protein Butorphanol results in increased activity of OPRM1 protein |
CTD |
PMID:17909753 PMID:32734307 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Prkcd |
protein kinase C, delta |
affects localization |
ISO |
Butorphanol affects the localization of PRKCD protein |
CTD |
PMID:29669290 |
|
NCBI chr16:5,769,226...5,807,214
Ensembl chr16:5,769,215...5,799,352
|
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
canadine results in increased expression of CYP1A2 mRNA; canadine results in increased expression of CYP1A2 protein |
CTD |
PMID:28257954 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases expression |
ISO |
canadine results in increased expression of CYP2E1 mRNA; canadine results in increased expression of CYP2E1 protein |
CTD |
PMID:28257954 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
cephaelin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
cephaelin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
cephaelin results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
cephaelin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
cephaelin results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases activity |
ISO |
cepharanthine results in decreased activity of ABCB1 protein |
CTD |
PMID:15958061 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
cepharanthine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
increases expression |
ISO |
cepharanthine results in increased expression of MCL1 protein |
CTD |
PMID:31255635 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
cepharanthine results in decreased expression of MTOR protein |
CTD |
PMID:31255635 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
cepharanthine results in decreased expression of PARP1 protein |
CTD |
PMID:31255635 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
cepharanthine results in increased expression of TP53 protein |
CTD |
PMID:31255635 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] chelerythrine results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] |
CTD |
PMID:10037446 PMID:15364539 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [sodium arsenite inhibits the reaction [Cisplatin results in increased expression of BAX protein]] |
CTD |
PMID:12690470 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
chelerythrine inhibits the reaction [sodium arsenite inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]] chelerythrine inhibits the reaction [Resveratrol affects the expression of BCL2 protein] |
CTD |
PMID:12690470 PMID:31151226 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Capsaicin results in increased expression of CALCA protein] |
CTD |
PMID:18752301 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp2 |
caspase 2 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of CASP2 protein |
CTD |
PMID:26124276 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
EXP ISO |
malonic acid inhibits the reaction [chelerythrine results in increased activity of CASP3 protein]; Rotenone inhibits the reaction [chelerythrine results in increased activity of CASP3 protein] Acetylcysteine inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; Dithiothreitol inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; quinoline-val-asp(OMe)-CH2-OPH inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein]; S-methyl glutathione inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein] |
CTD |
PMID:21664962 PMID:26124276 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of CASP6 protein |
CTD |
PMID:26124276 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of CASP7 protein |
CTD |
PMID:26124276 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage increases activity |
EXP ISO |
malonic acid inhibits the reaction [chelerythrine results in increased activity of CASP9 protein]; Rotenone inhibits the reaction [chelerythrine results in increased activity of CASP9 protein] chelerythrine results in increased cleavage of CASP9 protein |
CTD |
PMID:21664962 PMID:26124276 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [CASR protein results in increased uptake of Calcium] |
CTD |
PMID:21562303 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Phenylephrine results in increased expression of CCN1 mRNA] |
CTD |
PMID:15117851 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases activity |
ISO |
chelerythrine results in decreased activity of CFTR protein |
CTD |
PMID:14744818 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] |
CTD |
PMID:16901605 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [CYP1B1 protein results in increased metabolism of 9,10-Dimethyl-1,2-benzanthracene]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; chelerythrine promotes the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]] |
CTD |
PMID:10037446 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:18436224 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [EGF protein inhibits the reaction [Acetaldehyde affects the localization of TJP1 protein]]; chelerythrine inhibits the reaction [EGF protein results in decreased susceptibility to Acetaldehyde] |
CTD |
PMID:17991733 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Glucose results in increased expression of FN1 protein] |
CTD |
PMID:12388107 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
EXP |
chelerythrine results in decreased activity of G6PD protein |
CTD |
PMID:19429815 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Acrolein results in increased secretion of GPT protein]; chelerythrine inhibits the reaction [allyl alcohol results in increased secretion of GPT protein] |
CTD |
PMID:12755590 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [sodium arsenite results in increased expression of HSPA1A protein] |
CTD |
PMID:12690470 |
|
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein] |
CTD |
PMID:16178011 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects activity |
EXP |
chelerythrine affects the activity of IGF1 protein |
CTD |
PMID:11548882 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of IL1B mRNA]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of IL1B protein] |
CTD |
PMID:34006824 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Acids results in increased expression of IL6 mRNA]; chelerythrine inhibits the reaction [Acids results in increased secretion of IL6 protein] chelerythrine inhibits the reaction [Ethanol results in increased expression of IL6 protein]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of IL6 mRNA]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of IL6 protein] |
CTD |
PMID:19074641 PMID:24300194 PMID:34006824 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
EXP |
chelerythrine results in decreased phosphorylation of and results in decreased activity of JAK2 protein |
CTD |
PMID:15746188 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kcnd3 |
potassium voltage-gated channel subfamily D member 3 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Phenylephrine results in decreased activity of KCND3 protein alternative form] |
CTD |
PMID:11709419 |
|
NCBI chr 2:192,937,950...193,155,345
Ensembl chr 2:192,937,950...193,155,345
|
|
G |
Lmna |
lamin A/C |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of LMNA protein |
CTD |
PMID:26124276 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] chelerythrine inhibits the reaction [Estradiol results in increased activity of MAPK1 protein] chelerythrine inhibits the reaction [CXCL8 protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:10037446 PMID:14511371 PMID:15831558 PMID:16713447 PMID:19854188 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
chelerythrine inhibits the reaction [CXCL8 protein results in increased phosphorylation of MAPK3 protein] chelerythrine inhibits the reaction [Estradiol results in increased activity of MAPK3 protein] chelerythrine inhibits the reaction [[Lead co-treated with Lipopolysaccharides] results in increased phosphorylation of MAPK3 protein]; chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; chelerythrine inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:10037446 PMID:14511371 PMID:15831558 PMID:16581537 PMID:16713447 PMID:19854188 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[AG 1879 co-treated with chelerythrine] inhibits the reaction [CXCL8 protein results in increased secretion of MMP9 protein] |
CTD |
PMID:15831558 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:24300194 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Resveratrol affects the expression of MYC protein] |
CTD |
PMID:31151226 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:18436224 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased degradation of NFKBIA protein] |
CTD |
PMID:34006824 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[chelerythrine co-treated with tyrphostin 47] inhibits the reaction [Quercetin results in increased expression of NOS3 protein] |
CTD |
PMID:22557973 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; chelerythrine promotes the reaction [2-aminoethoxydiphenyl borate inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]] |
CTD |
PMID:16787574 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nts |
neurotensin |
increases activity |
ISO |
chelerythrine results in increased activity of NTS protein |
CTD |
PMID:18313772 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Testosterone results in increased expression of PCNA mRNA] |
CTD |
PMID:21374593 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Capsaicin results in increased expression of PRKCA protein] |
CTD |
PMID:18752301 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
ISO EXP |
chelerythrine inhibits the reaction [Calcium results in increased phosphorylation of PRKCE protein] [chelerythrine results in decreased activity of PRKCE protein] which results in decreased susceptibility to Phenylephrine |
CTD |
PMID:12700091 PMID:21562303 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of PTGES3 protein |
CTD |
PMID:26124276 |
|
NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Acids results in increased activity of RELA protein]; chelerythrine inhibits the reaction [Glucose results in increased activity of RELA protein] chelerythrine inhibits the reaction [Ethanol results in increased expression of RELA protein]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of RELA protein] |
CTD |
PMID:12388107 PMID:19074641 PMID:24300194 PMID:34006824 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
decreases activity multiple interactions |
EXP |
chelerythrine results in decreased activity of SLC1A1 protein chelerythrine inhibits the reaction [Pregabalin results in increased activity of SLC1A1 protein]; chelerythrine inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein] |
CTD |
PMID:17382927 PMID:22511482 PMID:23262392 PMID:23602688 PMID:24355585 |
|
NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
|
|
G |
Slc5a6 |
solute carrier family 5 member 6 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [SLC5A6 protein results in increased transport of Biotin] |
CTD |
PMID:15561972 |
|
NCBI chr 6:25,319,187...25,331,713
Ensembl chr 6:25,320,442...25,331,712
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
increases cleavage |
ISO |
chelerythrine results in increased cleavage of SPTAN1 protein |
CTD |
PMID:26124276 |
|
NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
multiple interactions |
EXP |
chelerythrine results in decreased phosphorylation of and results in decreased activity of STAT5A protein |
CTD |
PMID:15746188 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of TH mRNA]; chelerythrine inhibits the reaction [HU 211 results in decreased expression of TH mRNA] |
CTD |
PMID:18992715 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [EGF protein inhibits the reaction [Acetaldehyde affects the localization of TJP1 protein]] |
CTD |
PMID:17991733 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Ethanol results in increased expression of TNF protein]; chelerythrine inhibits the reaction [lead acetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; chelerythrine inhibits the reaction [lead acetate results in increased expression of TNF protein]; chelerythrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TNF mRNA]; chelerythrine inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of TNF protein]; chelerythrine inhibits the reaction [TNF protein results in increased transport of Chlorides]; chelerythrine inhibits the reaction [TNF protein results in increased transport of Potassium] |
CTD |
PMID:10783394 PMID:15302094 PMID:16581537 PMID:24300194 PMID:34006824 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of TNNI3 protein] |
CTD |
PMID:12003851 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
ISO |
chelerythrine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of TNNT2 protein] |
CTD |
PMID:12003851 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
chelerythrine inhibits the reaction [Capsaicin results in increased expression of TRPV1 protein] |
CTD |
PMID:18752301 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects expression |
ISO |
chelidonine affects the expression of BAX mRNA |
CTD |
PMID:25265580 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression |
ISO |
chelidonine affects the expression of BCL2 mRNA |
CTD |
PMID:25265580 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases metabolic processing |
ISO |
[CYP1A2 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog |
CTD |
PMID:31102647 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases metabolic processing multiple interactions |
ISO |
CYP2C19 protein results in increased metabolism of chelidonine [CYP2C19 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog |
CTD |
PMID:31102647 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing multiple interactions |
ISO |
CYP2D6 protein results in increased metabolism of chelidonine [CYP2D6 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog |
CTD |
PMID:31102647 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions |
ISO |
CYP3A4 protein results in increased metabolism of chelidonine [CYP3A4 protein results in increased metabolism of chelidonine] which results in increased abundance of Glutathione analog |
CTD |
PMID:31102647 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dapk1 |
death associated protein kinase 1 |
affects expression |
ISO |
chelidonine affects the expression of DAPK1 mRNA |
CTD |
PMID:25265580 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
chelidonine results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
chelidonine results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity decreases expression |
ISO |
chelidonine results in decreased activity of TERT protein chelidonine results in decreased expression of TERT mRNA |
CTD |
PMID:25265580 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
Codeine results in increased secretion of CCL2 protein |
CTD |
PMID:17441793 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Codeine affects the secretion of and affects the expression of CCL5 protein |
CTD |
PMID:17441793 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis |
ISO |
CES2 protein results in increased hydrolysis of Codeine analog |
CTD |
PMID:25445008 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing multiple interactions increases metabolic processing affects response to substance decreases methylation |
ISO |
CYP2D6 protein affects the metabolism of Codeine; CYP2D6 protein polymorphism affects the metabolism of Codeine [CYP2D6 gene mutant form results in increased activity of CYP2D6 protein] which results in increased susceptibility to Codeine; [CYP2D6 protein results in increased metabolism of Codeine] which results in increased chemical synthesis of Morphine [CYP2D22 protein results in increased metabolism of Codeine] which results in increased chemical synthesis of norcodeine CYP2D6 protein polymorphism affects the susceptibility to Codeine CYP2D6 protein results in decreased methylation of Codeine CYP2D6 gene polymorphism results in increased metabolism of Codeine; CYP2D6 protein results in increased metabolism of Codeine |
CTD |
PMID:9696456 PMID:10911933 PMID:11823760 PMID:15286053 PMID:15625333 PMID:16595712 PMID:17470523 PMID:17564651 PMID:21241245 More...
|
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing increases metabolic processing multiple interactions |
ISO |
CYP3A4 protein affects the metabolism of Codeine CYP3A4 protein results in increased metabolism of Codeine [CYP3A4 protein results in increased metabolism of Codeine] which results in increased chemical synthesis of norcodeine |
CTD |
PMID:15286053 PMID:16595712 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Codeine results in decreased activity of KCNH2 protein |
CTD |
PMID:19034038 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
affects binding |
EXP |
Codeine binds to OPRD1 protein |
CTD |
PMID:7562497 |
|
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
affects binding |
EXP |
Codeine binds to OPRK1 protein |
CTD |
PMID:7562497 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
affects binding |
EXP |
Codeine binds to OPRM1 protein |
CTD |
PMID:7562497 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
6-codeinone results in increased expression of BAX protein |
CTD |
PMID:12894543 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
6-codeinone results in decreased expression of BCL2 protein |
CTD |
PMID:12894543 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage |
ISO |
6-codeinone results in increased activity of CASP3 protein 6-codeinone results in increased cleavage of CASP3 protein |
CTD |
PMID:12606908 PMID:12894543 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
6-codeinone results in increased activity of CASP9 protein |
CTD |
PMID:12894543 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
6-codeinone affects the localization of CYCS protein |
CTD |
PMID:12894543 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
|
G |
Cdh5 |
cadherin 5 |
increases expression |
ISO |
columbamine results in increased expression of CDH5 mRNA |
CTD |
PMID:23124089 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
columbamine results in decreased expression of CDK6 mRNA; columbamine results in decreased expression of CDK6 protein |
CTD |
PMID:23124089 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
columbamine inhibits the reaction [CSF2 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:23124089 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
multiple interactions |
ISO |
[Xiao-Ke-An results in increased abundance of columbamine] which results in decreased activity of DPP4 protein |
CTD |
PMID:32535096 |
|
NCBI chr 3:46,962,243...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression |
ISO |
columbamine results in decreased expression of EPHB2 mRNA |
CTD |
PMID:23124089 |
|
NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
ISO |
columbamine results in increased phosphorylation of GSK3B protein |
CTD |
PMID:32535096 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Maged1 |
MAGE family member D1 |
decreases expression |
ISO |
columbamine results in decreased expression of MAGED1 mRNA |
CTD |
PMID:23124089 |
|
NCBI chr X:59,422,715...59,429,381
Ensembl chr X:59,422,717...59,429,364
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
columbamine results in decreased expression of MMP2 mRNA |
CTD |
PMID:23124089 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Sox17 |
SRY-box transcription factor 17 |
decreases expression |
ISO |
columbamine results in decreased expression of SOX17 mRNA |
CTD |
PMID:23124089 |
|
NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
columbamine inhibits the reaction [CSF2 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:23124089 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
ISO |
corynoline results in increased phosphorylation of GSK3B protein |
CTD |
PMID:34477289 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
corynoline promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein] |
CTD |
PMID:34477289 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein] |
CTD |
PMID:34477289 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of MPO protein] |
CTD |
PMID:34477289 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
corynoline promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFE2L2 protein] |
CTD |
PMID:34477289 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:34477289 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] |
CTD |
PMID:34477289 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein] |
CTD |
PMID:34477289 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases glutathionylation multiple interactions |
ISO |
CYP3A4 protein results in increased glutathionylation of dauricine [CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of N-desmethyldauricine; [CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of quinone methide; CYP3A4 protein results in increased oxidation of and results in increased activity of dauricine; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased glutathionylation of dauricine] |
CTD |
PMID:19358519 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
rostafuroxin inhibits the reaction [Dextromethorphan results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:34740715 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP |
Dizocilpine Maleate inhibits the reaction [Dextromethorphan results in increased expression of BAX protein]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in increased expression of BAX protein] |
CTD |
PMID:28916251 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP |
traxoprodil mesylate inhibits the reaction [Dextromethorphan results in decreased expression of BCL2 protein] |
CTD |
PMID:28916251 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
EXP |
Dextromethorphan results in decreased expression of BCL2L1 protein Dizocilpine Maleate inhibits the reaction [Dextromethorphan results in decreased expression of BCL2L1 protein]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in decreased expression of BCL2L1 protein] |
CTD |
PMID:28916251 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP |
Dizocilpine Maleate inhibits the reaction [Dextromethorphan results in increased cleavage of CASP3 protein]; traxoprodil mesylate inhibits the reaction [Dextromethorphan results in increased cleavage of CASP3 protein] |
CTD |
PMID:28916251 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression increases secretion |
ISO |
Dextromethorphan results in decreased expression of CCL2 protein Dextromethorphan results in increased secretion of CCL2 protein |
CTD |
PMID:19189960 PMID:32871113 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Dextromethorphan results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing |
ISO |
CYP1A2 protein affects the metabolism of Dextromethorphan |
CTD |
PMID:15199075 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Dextromethorphan results in decreased activity of CYP1B1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Dextromethorphan results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
affects metabolic processing |
EXP |
CYP2C13 protein affects the metabolism of Dextromethorphan |
CTD |
PMID:15879494 |
|
NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
affects metabolic processing |
ISO |
CYP2C19 protein affects the metabolism of Dextromethorphan |
CTD |
PMID:15286053 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
increases metabolic processing multiple interactions |
ISO |
CYP2D10 protein results in increased metabolism of Dextromethorphan [CYP2D10 protein results in increased metabolism of Dextromethorphan] which results in increased chemical synthesis of Dextrorphan |
CTD |
PMID:30503582 |
|
NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
decreases methylation multiple interactions increases metabolic processing |
|